| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to biotechnology. What is presented is using a monoclonal antibody or its fragment containing at least one variable domain of a heavy chain and at least one variable domain of a light chain of the antibody e20 and able to bind to HCV E2 glycoprotein of the genotypes 1a, 1b, 2a, 2b or 4 for neutralising hepatitis C virus (HCV) infection.EFFECT: present invention can find further application in the treatment and prevention of HVC infections.6 cl, 2 tbl, 3 dwg |
